Ruxolitinib During Stem Cell Transplant

Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
50 patients (estimated)
Tags
Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
SparkCures ID
2229
NCT Identifier
NCT07228624

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.